Ondrej Venglar

Ondrej Venglar

Auto-generated profile, based on publicly available information

Ondrej Venglar

Department of Hematooncology University Hospital Ostrava Ostrava Czech Republic

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
TJTomas Jelinek
Tomas Jelinek
RBRenata Bezdekova
Renata Bezdekova
DZDavid Zihala
David Zihala
TSTereza Sevcikova
Tereza Sevcikova
ASAnjana Anilkumar Sithara
Anjana Anilkumar Sithara
RHRoman Hajek
Roman Hajek
PURPOSE: Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels. METHODS: We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM-CLARIDEX trial. The largest published real-world cohort of patients with primary PCL was used for comparison of survival. Finally, we challenged the current 5% threshold for primary PCL diagnosis. RESULTS: Newly diagnosed transplant-ineligible patients with MM with 2%-20% CTCs had significantly shorter progression-free survival (3.1 v 15.6 months; P < .001) and overall survival (14.6 v 33.6 months; P = .023) than patients with < 2%. The 2% cutoff proved to be applicable also in transplant-eligible patients with MM and was successfully validated on an independent cohort of patients from the GEM-CLARIDEX trial. Most importantly, patients with 2%-20% CTCs had comparable dismal outcomes with primary PCL. Moreover, after revealing a low mean difference between flow cytometric and morphologic evaluation of CTCs, we showed that patients with 2%-5% CTCs have similar outcomes as those with 5%-20% CTCs. CONCLUSION: Our study uncovers that ≥ 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.

9 October 2023 in British Journal of Haematology
Verified
Journal Article
Open access
OVOndrej Venglar
Ondrej Venglar
VKVeronika Kapustova
Veronika Kapustova
ASAnjana Anilkumar Sithara
Anjana Anilkumar Sithara
DZDavid Zihala
David Zihala
LMLudmila Muronova
Ludmila Muronova
TJTomas Jelinek
Tomas Jelinek
Summary: Induction therapy followed by CD34+ cell mobilisation and autologous transplantation represents standard of care for multiple myeloma (MM). However, the anti‐CD38 monoclonal antibodies daratumumab and isatuximab have been associated with mobilisation impairment, yet the mechanism remains unclear. In this study, we investigated the effect of three different regimens (dara‐VCd, isa‐KRd and VTd) on CD34+ cells using flow cytometry and transcriptomics. Decreased CD34+ cell peak concentration and yields, longer collection and delayed engraftment were reproduced after dara‐VCd/isa‐KRd versus VTd induction in 34 patients in total. Using flow cytometry, we detected major changes in the proportion of apheresis product and bone marrow CD34+ subsets in patients treated with regimens containing anti‐CD38 therapy; however, without any decrease in CD38high B‐lymphoid progenitors in both materials. RNA‐seq of mobilised CD34+ cells from 21 patients showed that adhesion genes are overexpressed in CD34+ cells after dara‐VCd/isa‐KRd and JCAD, NRP2, MDK, ITGA3 and CLEC3B were identified as potential target genes. Finally, direct in vitro effect of isatuximab in upregulating JCAD and CLEC3B was confirmed by quantitative PCR. These findings suggest that upregulated adhesion‐related interactions, rather than killing of CD34+ cells by effector mechanisms, could be leading causes of decreased mobilisation efficacy in MM patients treated with anti‐CD38 therapy.

14 November 2025 in Blood Cancer Discovery
Verified
Journal Article
Open access
ASAnjana Anilkumar Sithara
Anjana Anilkumar Sithara
VKVeronika Kapustová
Veronika Kapustová
DZDavid Zihala
David Zihala
OVOndrej Venglar
Ondrej Venglar
DBDaniel Bilek
Daniel Bilek
TJTomas Jelinek
Tomas Jelinek
Extramedullary multiple myeloma (EMM) is a high-risk feature of multiple myeloma associated with increased resistance to treatments, including modern immunotherapies, and shorter survival. The composition and functional state of immune cells within the EMM tumor microenvironment (TME) remain poorly understood. Using single-cell RNA sequencing, flow cytometry, and spatial transcriptomics, we revealed significant differences in the EMM TME compared with multiple myeloma bone marrow (BM). T and NK cells were verified as the most abundant immune subsets in the EMM TME. Compared with the BM counterparts, we found these tumors to have a significantly reduced effector–to–tumor cell ratio, a significantly lower number of CD4+ T cells, and an increased proportion of regulatory CD16− NK cells. We observed a high proportion of exhausted, tumor-reactive CD8+ T cells in roughly half of EMM tumors. Furthermore, we identified elevated expression of immune checkpoints, such as PD-1 on CD8+ T cells and KLRC1 (NKG2A) on CD16− NK cells. Significance: This study characterizes the TME in EMM lesions and paired BM from patients with multiple myeloma, revealing a high proportion of less cytotoxic CD16− NK cells in EMM tumors and suggesting that direct cell–cell interactions may underlie the CD8+ T-cell exhaustion observed in a subset of these tumors.

24 September 2025 in Cytometry Part A
Verified
Journal Article
Open access
OVOndrej Venglar
Ondrej Venglar
EREva Radova
Eva Radova
LBLucie Broskevicova
Lucie Broskevicova
RHRoman Hajek
Roman Hajek
TJTomas Jelinek
Tomas Jelinek
The analysis of immune cell compartments in cancer patients is crucial to predict treatment efficacy and relapse. We introduce a robust 40‐parameter, 37‐channel spectral cytometry panel designed to profile human lymphoid subsets and CAR‐T cell expansion, with the capability to assess exhaustion status by profiling immune checkpoints and activating receptors in cancer patients. Developed for the 5‐laser Cytek Aurora, the panel optimizes fluorophore selection and uses three pairs of mutually exclusive markers assigned to a single fluorescent parameter to simplify setup and ensure robust data, adopting a conservative design choice to keep similarity indices below 0.85; though higher overlaps can still yield high‐quality data when best practices are applied. The panel enables detailed analysis of well‐defined lymphoid subsets using a conventional gating strategy, as well as detection of unconventional subsets with variable expression patterns by unsupervised algorithm‐based analysis. The effectiveness of the panel is demonstrated through a dataset simulating the progression of multiple myeloma, from pre‐malignant disease to a highly aggressive stage.

15 January 2025 in American Journal of Hematology
Verified
Journal Article
Open access
OVOndrej Venglar
Ondrej Venglar
EREva Radova
Eva Radova
DZDavid Zihala
David Zihala
ITIvana Tvrda
Ivana Tvrda
VKViktor Kubala
Viktor Kubala
TJTomas Jelinek
Tomas Jelinek

5 November 2021 in Blood
Verified
Journal Article
Open access
TJTomas Jelinek
Tomas Jelinek
RBRenata Bezdekova
Renata Bezdekova
DZDavid Zihala
David Zihala
TSTereza Sevcikova
Tereza Sevcikova
LCLenka Capkova
Lenka Capkova
RHRoman Hajek
Roman Hajek
Background: Tumor burden in multiple myeloma (MM) is routinely evaluated in the bone marrow, though its prognostic value is not proven. There is an increasing interest in liquid biopsies due to its minimally invasive nature and more comprehensive evaluation of tumor burden. Growing evidence supports the quantification of circulating plasma cells (cPCs) measured by multiparameter flow cytometry (MFC) as a powerful diagnostic biomarker suitable for risk stratification of newly diagnosed transplant eligible MM (Garces et al, EHA 2021). Nevertheless, there are virtually no data regarding prognostic impact of cPCs in MM patients ineligible for transplantation. Primary plasma cell leukemia (pPCL) is a rare and most aggressive monoclonal gammopathy with dismal outcomes defined by more than 20% of cPCs and/or absolute cPCs count of ≥2 x10 9/L. Recently, there have been many efforts to redefine these criteria as lower number of cPCs probably portends equally poor prognosis. Aims: To evaluate prognostic significance of cPCs in a large cohort of transplant ineligible (Tx-ineligible) newly diagnosed MM patients and to define cut-offs for risk stratification. Moreover, to establish cut-off identifying ultra high risk MM patients mimicking the prognosis of pPCL and propose new definition of pPCL. Methods: Circulating PCs were measured by 8 color flow cytometry in 402 Tx-ineligible MM patients (including n=7 pPCL) diagnosed between 2012 and 2019 at University Hospitals Brno and Ostrava, Czech Republic. Patients were treated in real-world setting and the clinical analysis was performed retrospectively based on data from the Czech Registry of Monoclonal Gammopathies. Median follow-up was 20.5 months. The intermediate cutoff was identified using ROC analysis considering overall survival (OS). Moreover, data from the large published cohort of pPCL patients treated in real-world setting were used to find a new cut-off identifying these ultra-high-risk pPCL-like patients (Jurczyszyn et al. BJH,2018). Results: Circulating PCs were detected in peripheral blood (PB) of 303/402 (75%) patients. In 303 patients with detectable cPCs the median percentage was 0.06% with range 0.0008% - 79%. The median limit of detection of MFC technique was 0.006 (sensitivity 10e-5). Patients stratification into 3 subgroups according to quantification of cPCs (low: ≤ 0.2%; intermediate: 0.2 - 2% and high: >2.0%) resulted in significantly different OS (36.5 vs. 28.1 and 13.6 months; p < 0.0001) and progression free survival (PFS) (17.9 vs. 14.7 and 3.4 months; p < 0.0001). Patients with no detected cPCs (0%) did not separate from subgroup >0% to 0.05) suggesting that next-generation flow cytometry (NGF) with sensitivity 10e-6 is needed for the identification of this favorable prognostic group. In order to demonstrate that patients with more than 2% of cPCs have similarly poor outcome as pPCL patients, we compared those with 2% - 20% (n=15) vs. those with >20% (n=7) of cPCs. The outcomes were practically identical with median PFS of 3.1 vs. 4.2 months (p = 0.23) and median OS of 13.6 vs. 14.6 months (p=0.23). Next, we analyzed patient´s characteristics in association with the level of cPCs (low, intermediate and high) and we demonstrated that there was significantly higher proportion of patients with ISS III stage (38%, 52% and 82%), elevated LDH level (8%, 19% and 55%) and high risk cytogenetics (12%, 21% and 36%) hand in hand with increasing number of cPCs. CPCs were identified as the most powerful prognostic marker in univariate (HR=2.7 for OS and HR=6.3 for PFS; p=0.001) and multivariate analysis (HR=4.2 for OS and HR=5.8 for PFS; p<0.001), including ISS, LDH and FISH cytogenetics. Conclusion: The quantification of cPCs in PB of newly diagnosed MM is the most powerful prognostic factor as we demonstrated on a large cohort of transplant ineligible patients. We defined 2% of cPCs as a new cut-off for ultra high risk myeloma resembling behavior of primary PCL. We propose this 2% cut-off for redefinition of pPCL criteria that warrants further investigation in prospective setting. To identify subgroup with especially favorable outcome with no detectable cPCs, NGF with high sensitivity of 10e-6 is needed. Quantification of cPCs by MFC is easy, fast, affordable and worldwide available procedure providing highly relevant prognostic information that might be implemented into routine clinical practice.